Shaoying Li, MD
Department of Hematopathology
University of Texas
MD Anderson Cancer Center
1515 Holcombe Blvd, Unit 0072
Houston, Texas 77030, USA
Dr. Li has received her MD from Beijing Medical University (Current name: Peking University Health Science Center). She is currently an Assistant Professor in the Department of Hematopathology at the University of Texas, MD Anderson Cancer Center. She is board certified by the American Board of Pathology in Anatomic Pathology, Clinical Pathology, and Hematology. In addition to clinical responsibilities on Lymphoma, leukemia and flow cytometryservices, Dr. Li has been actively participating in multiple research projects in lymphoma and leukemia, which has led to over 30 research papers and multiple book chapters. She also serves as members of editorial boards and ad hoc reviewers for multiple journals. Her major research interests include molecular cytogenetic risk stratification of DLBCL with a focus on “double hit” lymphoma and MYC/BCL2 double expresser lymphoma, clinicopathologic and molecular study of mantle cell lymphoma, and molecular genetic aberrations in lymphoma and leukemia.
Her Research interest includes: Molecular cytogenetic risk stratification of DLBCL. Double hit lymphoma and MYC/BCL2 double expresser lymphoma. Clinicopathologic and molecular study of mantle cell lymphoma.Molecular genetic aberrations in lymphoma and leukemia.
HONORS AND AWARDS
• (2011-2014) Mentor for residents of several departmental translational research Awards
• (2009) One of the finalists of the 2009 American Journal of Clinical Pathology Resident Research Symposium, Chicago
• (2008) UAB Department of Pathology Resident Research Award
• (1997) International Society of Nephrology Young Scholar Travel Award
• (1996) Beijing Medical University Graduate School Guanghua Award
• (1990) Beijing Medical University Honored Graduate & Preselected Ph.D. Candidate exempting of entrance examinations
SELECTED PEER REVIEWED PUBLICATIONS
1. Li S, Weiss VL, Wang XJ, et al. High-Grade B cell Lymphoma with MYC Rearrangement and without BCL2 and BCL6 Rearrangements Is Associated with High P53 Expression and a Poor Prognosis. Am J Surg Pathol. 2015.
2. Wang XJ, Medeioros LJ, Lin P, et al. MYC Cytogenetic Status Correlates with Expression and Has Prognostic Significance in Patients with MYC/BCL2 Protein Double-Positive Diffuse Large B Cell Lymphoma. Am J Surg Pathol. 2015; 39: 1250-1258.
3. Tang G, Fu B, Hu S, et al. Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia. Am J Hematol. 2015. doi: 10.1002/ajh.24108
4. Cao X, Ye Q, Orlowski RZ, et al. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol. 2015; 8(1): 74. doi: 10.1186/s13045-015-0172-y
5. Yin CC, Peng J, Li Y, et al. Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. Mod Pathol. 2015. doi: 10.1038/modpathol.2015.66
6. Li Y, Hu S, Zuo Z, et al. CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Mod Pathol. 2015; 28: 787-798.
7. Wang W, Tang G, Cortes JE, et al. Chromosomal Rearrangement Involving 11q23 Locus in Chronic Myelogenous Leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol. 2015; 8(1): 32. doi: 10.1186/s13045-015-0128-2
8. Li S, Seegmiller A, Lin P, et al. High-Grade B-Cell Lymphomas with Concurrent MYC and BCL2 Abnormalities Other than Translocations Behave Similarly to MYC/BCL2 Double-Hit Lymphomas. Mod Pathol. 2015; 28: 208-217.
9. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of Induction Regimen and Stem Cell Transplantation on Outcomes in Patients with Double Hit Lymphoma: A Large Multicenter Retrospective Analysis. Blood. 2014; 124(15): 2354-2361. doi: 10.1182/blood-2014-05-578963
10. Wang XI, Lu X, C Cameron Yin, et al. Myeloid Neoplasms Associated with t(3;12)(q26.2;p13) Are Clinically Aggressive and Frequently Harbor FLT3 Mutations: A Report of 8 Cases and Review of Literature. J Leuk. 2014; 3: 161. doi: 10.4172/2329-6917.1000161
11. Jonathan Douds, Long DJ, Kim AS, Li S. Diagnostic and Prognostic significance of CD200 Expression in Plasma Cell Myeloma. J Clin Pathol. 2014; 67: 792-796.
12. Tsai J, Iams w, Greer JP, Morgan DS, Li S, Reddy N. Alternate Intensive Induction Chemotherapeutic Regimens in MYC Expressing Diffuse Large B-Cell Lymphoma. Leuk Lymphoma. 2015; 56: 797-800.
13. Wang X, Li S. Immunohistochemical Analysis Using a BRAF V600E Mutation Specific Antibody is Highly Sensitive and Specific for the Diagnosis of Hairy Cell Leukemia. Int J Clin Exp Pathol. 2014; 7(7): 4323-4328.
14. Xu J, Li S. Unusual T Lymphoblastic Blast Phase of Chronic Myelogenous Leukemia. Case Rep Hematol. 2014; 2014: 304359. doi: 10.1155/2014/304359
15. Frank R, Li S, Ahmad NA, Sepulveda AR, Jhala NC. Mesothelin expression in pancreatic mucinous cysts. Am J Clin Pathol. 2014; 142(3): 313-319. doi : 10.1309/AJCPDTTL2I5ECMFG
16. Li S, Lin P, Young KH, et al. MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma. Adv Anat Pathol. 2013; 20: 315-326. doi: 10.1097/PAP.0b013e3182a289f2
17. Li S, Feng X, Li T, et al. Extranodal NK/T-cell Lymphoma, Nasal Type: A Report of 73 Cases at MD Anderson Cancer Center. Am J Surg Pathol. 2013; 37: 14-23. doi: 10.1097/PAS.0b013e31826731b5
18. Hooper K, Mukhtar F, Li S, Eltoum IA. Diagnostic Error Assessment and Associated Harm of EUS-FNA of Neuroendocrine Neoplasms of the Pancreas. Cancer Cytopathology. 2013; 121: 653-60.
19. Li S, Yin CC, Medeiros LJ, Bueso-Ramos C, Lu G, Lin P. Myelodysplastic Syndrome/Acute Myeloid Leukemia with t(3;21)(q26;q22) Are Commonly Therapy Related Diseases Associated With Poor Outcome. Am J Clin Pathol. 2012; 138(1): 146-152.
20. Jaco J, Chen L, Li S, et al. CD5-Positive MALT Lymphoma: A Clinicopathologic Study of 14 Cases. Human Pathol. 2012; 43(9): 1436-1443. doi: 10.1016/j.humpath.2011.11.004
21. Li S, Lin P, Fayad L, et al. B-Cell Lymphomas with MYC/8q24 Rearrangements and IGH@BCL2/t (14;18): An Aggressive Disease with Heterogeneous Histology and Poor Outcome. Mod Pathol. 2012; 25: 145-156. doi: 10.1038/modpathol.2011.147
22. Li S, Wan M, Cao X, Ren YS. Expression of AIF and HtrA2/Omi in CLL/SLL and DLBCL. Arch Pathol Lab Med. 2011; 135: 903-908.
23. Li S, Yan ZJ, Jhala N, Jhala D. Fine Needle Aspiration Diagnosis of Rosai-Dorfman Disease in An Osteolytic Lesion of Bone. CytoJournal. 2010; 7:12. doi: 10.4103/1742-6413.65058
24. Li S, Siegal GP. Small Cell Tumors of Bone. Advances in Anatomic Pathology. 2010; 17 (1): 1-11. doi: 10.1097/PAP.0b013e3181bb6b9c
25. Li S, Ali S, Owens C, Kulesza P. Intra-pancreatic Schwannoma Diagnosed by Endoscopic Ultrasound-Guided Fine Needle Aspiration Cytology. Diagn Cytopathol. 2009; 37(2): 132-135. doi: 10.1002/dc.20985
26. Li S, Faye-Petersen OM, Reilly SD. Intestinal obstruction in a term stillborn infant. Lab Medicine. 2008; 39: 410-412. doi: 10.1309/DPGEAQRAY9D3UVU0
27. Li S, Benjamin Jr. W, Ho KJ. Fatal Strongyloides Hyperinfection Syndrome in a 66-Year-Old Woman Receiving Steroid Therapy. Lab Medicine. 2008; 39: 29-32. doi: 10.1309/04U9YEJKWW93AG6J
28. Li S, Sato S, Yang X, Preisig PA, Alpern RJ. Pyk2 activation is integral to acid stimulation of sodium/hydrogen exchanger 3. J Clin Invest. 2004; 114(12): 1782-1789.
29. Li S, Zhu S, Wang H. The Polymorphism of Two Microsatellites Closely Linked to the Locus for Polycystic Kidney Disease 1 in Chinese Population. Chinese J of Med Genet. 1998; 15(6): 360-363.
30. Li S, Zhu S, Wang H. The Polymorphism of Two Microsatellites – KG8 and CW2. J of Beijing Med Univ. 1998; 30(3): 213-215.
31. Zhu S, Zhang H, Bai Q, Li S, Liu Y, Wang H. Gene Diagnosis of Chinese Families with Autosomal Dominant Polycystic Kidney Disease using PCR Method. J of Beijing Mel Univ. 1996; 28(6): 419-421.